REDMOND, Wash., Dec. 17 /PRNewswire/ -- Incisionless surgery is the most significant advancement in surgical medicine in decades. It is being rapidly adopted by a wide variety of academic and private hospitals around the world, with over 700 StomaphyX(TM) and EsophyX(TM) procedures already performed globally. Despite the fact that both StomaphyX(TM) and EsophyX(TM) just obtained FDA clearance this year, over 50 U.S. centers have already been trained to perform these Natural Orifice Surgery (NOS) procedures and over 20 additional groups are scheduled to be trained in December.
Today, 3 training centers that have performed over 40 StomaphyX cases
each and are starting to perform EsophyX cases are training surgeons in NOS
technique. Courses are offered twice per month, with either academic or
private setting options available. Current training centers include:
-- The Ohio State Medical Center in Columbus, Ohio
-- Munroe Regional Health Systems in Ocala, Florida
-- Mercy Medical Center in New York
Dr. Dean Mikami, Assistant Professor of Surgery at Ohio State University (OSU) who performed the first StomaphyX(TM) procedure in the U.S., started the first StomaphyX(TM) training center, and has trained the majority of surgeons, states, "I have been very impressed with the performance of the StomaphyX(TM) device and the evolution of the procedure. Before StomaphyX, I had very few options to offer my patients. We have been performing a wide variety of procedures with StomaphyX and are able to address multiple medical conditions with one procedure. It is clear that transoral surgery is the way of the future and we are pleased to be leading this medical advancement."
"It was clear to me from the moment I first saw StomaphyX that these incisionless procedures offer tremendous advantages," reports Dr. Todd Overcash, of the Florida Bariatric Center who is one of the original four surgeons trained in the U.S. and has personally performed over 60 StomaphyX and 10 EsophyX procedures. "With no scars, little recovery time, and significantly better safety, patients from all over the U.S. are contacting me seeking these procedures. Surgeons interested in developing their practice should not hesitate to adopt transoral surgical products." Surgeons coming to the training course in Ocala can observe how both StomaphyX(TM) and EsophyX(TM) fit in a busy private practice and can observe the live procedures from state-of-the-art observation facilities.
"This is the future of surgery and greatly reduces invasiveness and complications," said Dr. Shawn Garber, Chief of Bariatric Surgery at Mercy Medical Center. "EndoGastric Solutions is leading the way with by far the most advanced instrumentation that moves us many leaps less invasive than laparoscopy, since it eliminates both internal and external incisions. Now we can offer patients the substantive anatomical change of surgery without even a scar. Patients can go back to work as early as the next day and no one can tell they have had a procedure."
Thierry Thaure, Chief Executive Officer of EndoGastric Solutions, stated, "StomaphyX is a product that every surgeon doing Laparoscopic GI Surgery should have in their armamentarium. Interest in these products and procedures is tremendous and we now have 15-20 surgeons attending each training course. The technology is safe, easy to learn, and offers clinical benefits in solving the complications that can occur from surgery. We are enthusiastic that the strong response of our surgeons demonstrates that the surgical market is ready for Natural Orifice Surgery products such as StomaphyX(TM) and EsophyX(TM)."
The Ohio State University Medical Center will be offering a Continuing Medical Education (CME) certified live case course on February 29th, 2008 entitled "Leap into the Future with Advances in Transoral Foregut Surgery" that will highlight the EsophyX device, a live case TIF procedure, and StomaphyX procedures. Dr. Scott Melvin, Director of the Center for Minimally Invasive Surgery and chairman of the course, says, "EsophyX has the potential to significantly change the treatment algorithm for reflux disease. EsophyX allows for earlier treatment because of the reduced procedural risk and offers the solution patients and physicians have been waiting for."
About EndoGastric Solutions
EndoGastric Solutions (EGS) is a privately held corporation located in Redmond, Washington and Redwood City, California. EGS is a pioneer in developing incisionless transoral procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD), obesity and other GI conditions. EsophyX and StomaphyX are cleared by the FDA, CE marked, and available for sale in the U.S. and Europe.
For more information about EndoGastric Solutions, Inc., EsophyX(TM) and
StomaphyX(TM), please visit:
In the US: http://www.endogastricsolutions.com
In the EU: http://www.egseurope.eu
Other locations throughout the globe: http://www.egsglobal.net
For more information about the Ohio State University Medical Center
"Leap into the Future with Advances in Transoral Foregut Surgery" course
U.S. Physician Contact:
Larry K. Fulton
Senior Director of U.S. Sales
EndoGastric Solutions, Inc.
European Customer Contact:
General Manager, Europe
+33 6 7525 8382
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE EndoGastric Solutions, Inc.|
Copyright©2007 PR Newswire.
All rights reserved